Adults 18+ years, with a confirmed diagnosis of moderate to severe UC. Poor response or adverse consequences from anti-TNF agents, vedolizumab, or non-biologicals. Previous treatment with IL-12/23 antagonists, imminent colectomy, cancer, or active infections were excluded. This evidence concerns the gene TNF and cancer.